Ligand Pharmaceuticals (LGND) Issues FY18 Earnings Guidance

Doris Richards
February 25, 2018

California Public Employees Retirement System boosted its position in shares of Ligand Pharmaceuticals by 4.5% during the second quarter. Moreover, Bridgeway Capital Management Inc has 0.01% invested in the company for 134,920 shares. The stock decreased 1.06% or $1.66 during the last trading session, reaching $154.68. About 1.19 million shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has declined 2.87% since February 25, 2017 and is downtrending. It has underperformed by 19.57% the S&P500.

Pura Vida Investments Llc increased its stake in Merck & Co Inc (MRK) by 54.57% based on its latest 2017Q3 regulatory filing with the SEC. The shares were sold at an average price of $145.00, for a total value of $362,500.00. The biotechnology company reported $1.31 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.06 by $0.25. The stock decreased 0.44% or $0.15 during the last trading session, reaching $33.96.

1492 Mgmt Ltd Com holds 1.18% or 9,790 shares. It is down 0.00% since February 23, 2017 and is. It has outperformed by 0.16% the S&P500. Its down 5.92% from 1.75M shares previously. Schwab Charles Investment Management Inc. raised its holdings in Ligand Pharmaceuticals by 15.4% in the 3rd quarter.

Investors sentiment increased to 1.69 in Q3 2017. Its up 0.08, from 0.98 in 2017Q2. Assetmark invested in 242 shares. Steinberg Glob Asset Management reported 120,611 shares. State Of Wisconsin Inv Board holds 0.01% or 15,000 shares in its portfolio.

Ariel Investments Llc holds 0.19% of its portfolio in Ballantyne Strong, Inc for 2.65 million shares. Highbridge Limited invested in 235,840 shares. Principal Gru holds 161,597 shares. 22,046 were accumulated by Kopp Lc. Howland Cap Limited Liability Co stated it has 13,906 shares. The companyÂ's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Fincl Sense Advisors Inc holds 0.13% in Monsanto Company (NYSE:MON) or 2,039 shares. Perritt Capital Management Inc owns 100,000 shares or 0.16% of their USA portfolio. Ami Asset Mgmt holds 140,758 shares. One analyst has rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Therefore 83% are positive. Enbridge Inc. had 23 analyst reports since August 4, 2015 according to SRatingsIntel. The stock has a consensus rating of "Buy" and a consensus price target of $150.83. The firm earned "Buy" rating on Monday, September 21 by Roth Capital. The company was upgraded on Thursday, October 27 by Citigroup. The rating has been shown in a report on Wednesday, 15 November. The rating was maintained by Deutsche Bank on Tuesday, August 8 with "Hold". On Friday, September 9 the stock rating was maintained by Barclays Capital with "Overweight". The stock has "Buy" rating by Argus Research on Wednesday, January 20.

Since September 25, 2017, it had 0 buys, and 6 selling transactions for $6.90 million activity. The firm has "Buy" rating given on Friday, March 11 by Roth Capital. $1.38M worth of Monsanto Company (NYSE:MON) was sold by MIZELL STEVEN.

Since August 23, 2017, it had 0 insider purchases, and 6 sales for $10.58 million activity. 925 shares were sold by Sabba Stephen L, worth $126,956 on Wednesday, December 20.

In other Ligand Pharmaceuticals news, CEO John L. Higgins sold 9,000 shares of Ligand Pharmaceuticals stock in a transaction on Thursday, February 15th.

Investors sentiment decreased to 1.06 in 2017 Q3. Its up 0.45, from 1.24 in 2017Q2. It improved, as 19 investors sold LGND shares while 68 reduced holdings. 50 funds opened positions while 97 raised stakes. Roth Capital maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) rating on Wednesday, October 11. Blair William Il has invested 0.13% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Paloma Prns Mgmt owns 2,200 shares or 0% of their U.S. portfolio. Martingale Asset Mgmt Limited Partnership owns 7,601 shares. (NASDAQ:LGND) in the fourth quarter, reports. Tompkins Fincl holds 52,722 shares or 0.8% of its portfolio. Bnp Paribas Arbitrage invested 0% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Mason Street Advsrs Ltd Liability Corporation reported 5,298 shares. Adams Diversified Equity Fund holds 0.04% or 4,900 shares. Goldman Sachs has invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Riverhead Cap Management Ltd Limited Liability Company holds 0.01% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 2,234 shares. Sigma Planning holds 0.05% or 5,056 shares.

Healthinvest Partners Ab, which manages about $85.64M US Long portfolio, upped its stake in Mckesson Corp (NYSE:MCK) by 5,500 shares to 68,600 shares, valued at $10.54M in 2017Q3, according to the filing. HC Wainwright restated a "buy" rating and issued a $170.00 price target on shares of Ligand Pharmaceuticals in a research report on Friday, February 2nd. Therefore 40% are positive. Inc. had 79 analyst reports since August 13, 2015 according to SRatingsIntel. Craig Hallum boosted their price objective on Ligand Pharmaceuticals from $170.00 to $190.00 and gave the company a buy rating in a research note on Thursday. As per Monday, July 17, the company rating was maintained by Deutsche Bank. H.C. Wainwright maintained it with "Buy" rating and $157.0 target in Thursday, October 5 report. The firm has "Buy" rating by TH Capital given on Wednesday, September 30. The firm has "Buy" rating by Roth Capital given on Wednesday, October 11. Deutsche Bank lowered Ligand Pharmaceuticals from a "hold" rating to a "sell" rating and set a $105.00 price target for the a research report on Monday, November 20th. As per Tuesday, September 5, the company rating was reinitiated by H.C. Wainwright.

Other reports by Iphone Fresh

Discuss This Article